Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 11/20 | 0.47 |
| ▸ | CA1 | P00915 | 6/20 | 0.41 |
| ▸ | CA2 | P00918 | 6/20 | 0.41 |
| ▸ | CA9 | Q16790 | 6/20 | 0.41 |
| ▸ | CA12 | O43570 | 5/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | GNRHR | P30968 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1625969 | 0.89 | PTGER4 (0.51) | PTGER4CA1CA2CA9CA12 | |
| SCHEMBL1626558 | 0.89 | PTGER4 (0.51) | PTGER4CA1CA2CA9CA12 | |
| SCHEMBL1625934 | 0.87 | PTGER4 (0.49) | PTGER4CA1CA2CA9CA12 | |
| SCHEMBL1624490 | 0.86 | PTGER4 (0.49) | PTGER4CA1CA2CA9CA12 | |
| SCHEMBL27582965 | 0.86 | PTGER4 (0.52) | PTGER4CA1CA2CA9CA12 | |
| SCHEMBL1625352 | 0.85 | PTGER4 (0.46) | PTGER4CA1CA2CA9CA12 | |
| SCHEMBL1626723 | 0.85 | PTGER4 (0.47) | PTGER4CA1CA2CA9CA12 | |
| SCHEMBL1624384 | 0.84 | PTGER4 (0.52) | PTGER4CA1CA2CA9CA12 | |
| SCHEMBL1625565 | 0.84 | PTGER4 (0.64) | PTGER4CA1CA2CA9CA12 | |
| SCHEMBL1625577 | 0.83 | PTGER4 (0.53) | PTGER4CA1CA2CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6710054-B2 | CONTAINING SULFONYLAMINOCARBONYL GROUPS; PROSTAGLANDIN INHIBITORS | PFIZER INC | 2004-03-23 | — | — | US | disclosed |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2002-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | PTGER4 51/4885CA1 2229/4885CA2 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.